LU91367I2 - Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant - Google Patents

Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant

Info

Publication number
LU91367I2
LU91367I2 LU91367C LU91367C LU91367I2 LU 91367 I2 LU91367 I2 LU 91367I2 LU 91367 C LU91367 C LU 91367C LU 91367 C LU91367 C LU 91367C LU 91367 I2 LU91367 I2 LU 91367I2
Authority
LU
Luxembourg
Prior art keywords
adjuvant
influenza virus
optionally including
virus vaccine
reverse genetics
Prior art date
Application number
LU91367C
Other languages
English (en)
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91367(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916794.2A external-priority patent/GB9916794D0/en
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of LU91367I2 publication Critical patent/LU91367I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91367C 1999-07-14 2007-09-21 Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant LU91367I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14364599P 1999-07-14 1999-07-14
GBGB9916794.2A GB9916794D0 (en) 1999-07-16 1999-07-16 In vitro virus reconstitution
PCT/GB2000/002710 WO2001004333A1 (fr) 1999-07-14 2000-07-14 Reconstitution in vitro de virus a arn de polarite negative segmentes

Publications (1)

Publication Number Publication Date
LU91367I2 true LU91367I2 (fr) 2007-11-21

Family

ID=26315773

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91367C LU91367I2 (fr) 1999-07-14 2007-09-21 Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant

Country Status (12)

Country Link
EP (1) EP1194580B2 (fr)
AT (1) ATE353370T1 (fr)
AU (1) AU5998400A (fr)
CA (1) CA2379012C (fr)
CY (2) CY1106404T1 (fr)
DE (5) DE60033284T3 (fr)
DK (1) DK1194580T4 (fr)
ES (1) ES2278621T5 (fr)
FR (1) FR08C0046I2 (fr)
LU (1) LU91367I2 (fr)
NL (4) NL300301I2 (fr)
WO (1) WO2001004333A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140264A0 (en) 1998-06-12 2002-02-10 Sinai School Medicine Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
AU2002309133A1 (en) * 2001-04-17 2002-10-28 Institut Pasteur Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
WO2006083286A2 (fr) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Virus de la grippe porcine genetiquement modifie et ses applications
NZ556061A (en) 2004-12-24 2009-06-26 Solvay Biologicals Bv Rescue of influenza virus
WO2006088481A2 (fr) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Virus de la grippe equine genetiquement modifie et utilisations associees
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
EP1945252B1 (fr) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccins comprenant des antigènes de surface purifié, préparés à partir de virus influenza élevés en culture cellulaire, adjuvés avec squalène
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
DK2478916T3 (da) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
MX2008013388A (es) * 2006-04-19 2009-03-02 Medimmune Llc Metodos y composiciones para expresar arn viral en sentido negativo en celulas caninas.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
US8597661B2 (en) 2007-05-04 2013-12-03 Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
US8043856B2 (en) 2007-06-14 2011-10-25 Wisconsin Alumni Research Foundation Adenoviral vectors for influenza virus production
EP2045323A1 (fr) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Constructions linéaires d'expression pour la production de particules de virus influenza
US20100183671A1 (en) 2007-06-27 2010-07-22 Novartis Vaccines & Diagnostics GmbH & Co., KG Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
EP2233568A1 (fr) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Nouveau procédé pour la génération de virus d'ARN
WO2010091262A1 (fr) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Virus chimériques de la maladie de newcastle et leurs utilisations
CN105727281A (zh) 2009-02-10 2016-07-06 诺华股份有限公司 具有减少量的角鲨烯的流感疫苗
EP2396031A1 (fr) 2009-02-10 2011-12-21 Novartis AG Vaccins contre l'influenza possédant des quantités accrues d'antigène h3
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
EP3009145A1 (fr) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Vaccins pour le virus influenza et leurs utilisations
BE1019643A3 (fr) 2009-04-27 2012-09-04 Novartis Ag Vaccins de protection contre la grippe.
WO2011014504A1 (fr) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Vecteurs du virus de la grippe recombiné et utilisations de ceux-ci
CA2805505C (fr) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Virus de l'influenza chimeriques ayant une capacite reduite a s'associer a d'autres virus de l'influenza et utilisations desdits virus
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2011151470A2 (fr) 2010-06-02 2011-12-08 Avir Green Hills Biotechnology Research Development Trade Ag Nouveau procédé de génération d'un virus à arn
US9101653B2 (en) 2011-08-26 2015-08-11 Wisconsin Alumni Research Foundation Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
EP2708552A1 (fr) 2012-09-12 2014-03-19 Medizinische Universität Wien Virus de la grippe
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
BR112015017420A2 (pt) * 2013-01-23 2017-07-11 Novartis Ag recombinação de vírus influenza
US20140274806A1 (en) 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
CA2905272A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Virus de la maladie de newcastle et leurs utilisations
WO2014159960A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
WO2015196150A2 (fr) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
CL2014003146A1 (es) * 2014-11-20 2015-06-12 Univ Santiago Chile Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3320343B1 (fr) 2015-07-07 2020-09-02 Seqirus UK Limited Méthode de quantification d'hémagglutinine immunogène
US10494613B2 (en) 2015-08-28 2019-12-03 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
CN111363727B (zh) * 2020-01-20 2021-09-24 武汉大学 携带幽门螺杆菌的重组流感病毒、宿主细胞及其制备方法与应用
EP3896077A1 (fr) 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Particules de type virus de la grippe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
MXPA01010082A (es) * 1999-04-06 2002-04-24 Wisconsin Alumni Res Found Virus recombinantes de influenza para vacunas y terapia de genes.

Also Published As

Publication number Publication date
DE122008000056I1 (de) 2009-04-09
DK1194580T3 (da) 2007-04-10
WO2001004333A1 (fr) 2001-01-18
CA2379012C (fr) 2013-07-02
NL300301I1 (nl) 2008-01-02
NL300369I1 (nl) 2009-01-05
AU5998400A (en) 2001-01-30
NL300301I2 (nl) 2008-10-01
ATE353370T1 (de) 2007-02-15
DE122008000057I1 (de) 2009-04-09
EP1194580A1 (fr) 2002-04-10
DK1194580T4 (da) 2011-01-03
CY2007023I1 (el) 2009-11-04
EP1194580B2 (fr) 2010-08-25
DE122007000061I1 (de) 2007-12-20
DE60033284D1 (de) 2007-03-22
CY2007023I2 (el) 2009-11-04
ES2278621T5 (es) 2011-02-02
NL300368I2 (nl) 2017-08-03
FR08C0046I1 (fr) 2009-01-02
ES2278621T3 (es) 2007-08-16
DE60033284T3 (de) 2014-10-30
DE122007000070I1 (de) 2008-01-31
DE60033284T2 (de) 2007-10-25
NL300294I2 (nl) 2008-10-01
NL300294I1 (nl) 2007-12-03
EP1194580B1 (fr) 2007-02-07
NL300368I1 (nl) 2009-01-05
CA2379012A1 (fr) 2001-01-18
DE122007000061I2 (de) 2011-07-21
CY1106404T1 (el) 2010-07-28
FR08C0046I2 (fr) 2011-11-25

Similar Documents

Publication Publication Date Title
LU91367I2 (fr) Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
CA2205015A1 (fr) Procede de production d'agents biologiques dans un milieu de culture sans proteines
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
DE69535018D1 (de) Papillomavirus vakzine
GEP20084431B (en) Papilloma virus vaccine
YU17891A (sh) Dnk koja odgovara genomu virusa sa negativnim lancem rnk, i postupak za dobijanje infektivnih virusa sa negativnim lancem rnk
JP2013213034A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
NZ288254A (en) Method, including an ultracentrifugation step, for preparing an influenza virus, antigens obtained and applications thereof
ATE46920T1 (de) Viren und impfstoffe.
Palese et al. Development of novel influenza virus vaccines and vectors
MXPA02012255A (es) Secuencia de nucleotidos del genoma a/udorn/72(hen2) de influenza.
MY126520A (en) A reinforced immunogen for an inactivated vaccine against infectious disease caused by the group of japanese encephalitis virus and a method for producing the same
ATE427119T1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
WO2001092548A3 (fr) Vaccin, vecteur de therapie genique et procedes d'utilisation associes
RU95117005A (ru) Способ получения вакцинных штаммов вируса гриппа в для производства инактивированной и живой гриппозных вакцин
ATE489106T1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
WO2002056909A3 (fr) Moyens pour induire une reponse immune aux antigenes bacteriens polysaccharidiques et aux structures proteiques des capsides de virus
EP0972523A3 (fr) Méthode et compositions pour induire une immunité antivirale
RU99113870A (ru) Вакцинный штамм вируса краснухи "орлов-д" и способ получения вакцины против краснухи
KR960016906A (ko) 약독화 수두 생바이러스 백신 및 그의 제조방법
EP1275726A3 (fr) Procede de production de vaccins antigrippaux polyvalents composes d'hemagglutinine
Ash In Flew Influenza